Get the content you want anytime you want.
REGISTER NOW | SIGN IN
ARTICLE

FDA Approves Combination HIV-1/HIV-2 Test

SEP 01, 2020 | GRANT M. GALLAGHER
The US Food and Drug Administration (FDA) has approved a Roche polymerase chain reaction diagnostic (PCR) which allows both qualitative detection and differentiation for HIV diagnosis. 

The HIV-1/HIV-2 Qualitative will be available for use on the existing cobas 6800/8800 Systems.

It is an in vitro nucleic acid amplification test for the qualitative detection and differentiation of human immunodeficiency virus type 1 (HIV-1) and type 2 (HIV-2) RNA in human serum and plasma.

"The test provides healthcare professionals with a single result to confirm HIV diagnosis and differentiate HIV-1 and HIV-2, an important distinction needed to identify appropriate treatment options," a Roche statement reads.

50% of new HIV infections may be transmitted during what is known as the "acute period," 3 days to 3 weeks from the time of infection, according to data cited in the Roche statement.

This makes rapid diagnosis and connection to correct care essential in the fight against HIV/AIDS.

Regulators may have been motivated to go forward with approval by the fact that predominant serology-based testing methods rely on the ability to detect an antibody or antigen response. As a result, they can fail to identify an infection early on.

If a person is tested prior to having a detectable antibody or antigen response, a false sense of security and thus further HIV transmission is possible.

Roche argues that the sensitivity of PCR technology, which is used with the cobas HIV-1/HIV-2 Qualitative Test, can reduce this time-to-detection period by a week or more. 

“Roche is committed to improving diagnostic technologies in the fight against HIV/AIDS,” said Thomas Schinecker, the firm's CEO. “Being able to reliably determine a person’s HIV status and accurately diagnose which HIV type they may have is crucial for patients and healthcare providers in preventing further community transmission and selecting an individual’s best treatment options.” 
To stay informed on the latest in infectious disease news and developments, please sign up for our weekly newsletter.